Previous 10 | Next 10 |
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2022. “We are pleased with this qu...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022. Axonics is scheduled to pre...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the comprehensive launch of the Axonics F15 across the United States. The newly developed, long-liv...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2022 financial results after the market closes on Thursday, May 5, 2022. In conjuncti...
Axonics (NASDAQ:AXNX) launches its direct to consumer television advertising campaign "The Find Real Relief". The campaign is focused on women with any form of urinary incontinence, a large and significantly undertreated population and aims to reduce the stigma associated with these...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the launch of its direct to consumer television advertising campaign. The Find Real Relief ...
MedTech company Axonics (NASDAQ:AXNX) announced on Monday that the U.S. Food and Drug Administration (FDA) approved Axonics F15, its new recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS). Axonics F15 is designed to last for well over a decade inside the body without...
Axonics sets recharge-free neuromodulation benchmark with FDA labeling for 15+ years of functional life at typical stimulation parameters and 20+ years at lower energy settings Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and comme...
The following slide deck was published by Axonics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Axonics, Inc. 2021 Q4 - Results - Earnings Call Presentation
Axonics, Inc. (AXNX) Q4 2021 Earnings Conference Call February 24, 2022, 4:30 PM ET Company Participants Raymond Cohen – Chief Executive Officer & Director Neil Bhalodkar – Vice President of Investor Relations Dan Dearen – President & Chief Financial Officer Confe...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...